All In Biotech

Drug Trial Radar · NCT07563738

A 2-part Phase 1/2 Open-label Trial on ODM-212

A 2-part Phase 1/2 Open-label Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ODM-212 in Combination With Anti-cancer Therapy in Participants With Advanced Solid Tumours

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

229

Planned (sponsor's estimate)

Start

Mar 27, 2026

Primary completion

Sep 2029

Study completion Sep 2029

Sponsor

Sponsor type
Industry
First posted
May 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)

Conditions

  • Mesothelioma
  • Pancreatic Cancer
  • NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

  • ODM-212Drug

    ODM-212 40mg tablet

  • Ipilimumab and nivolumabDrug

    Ipilimumab: 1 mg/kg administered intravenously over 30 minutes every 6 weeks. Nivolumab: 360 mg administered intravenously over 30 minutes every 3 weeks.

  • Gemcitabine and nab-paclitaxelDrug

    Nab-paclitaxel 125 mg/m2 administered intravenously over 30 minutes on Days 1, 8 and 15 of each 28-day cycle. Gemcitabine 1000 mg/m2 administered intravenously over 30 minutes immediately after the completion of nab-paclitaxel administration on days 1, 8 and 15 of each 28-day cycle

  • sotorasibDrug

    Sotorasib total daily dose of 960 mg taken orally q.d. every day of the 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities and Adverse EventsTime frame: Through study completion, on average of 2 years

Locations

23 sites in 7 countries. Site status is shown where the registry gives one.

  • Valkyrie Clinical Trials

    Los Angeles, California · Recruiting

  • UC Irvine Health

    Orange, California · Recruiting

  • START Dallas-Fort Worth

    Fort Worth, Texas · Recruiting

  • NEXT Oncology

    Irving, Texas · Recruiting

  • NEXT Oncology Virginia

    Fairfax, Virginia · Recruiting

  • Aalborg Universitets hospital

    Aalborg, Denmark · Recruiting

  • Rigshospitalet University

    Copenhagen, Denmark · Recruiting

  • Helsinki University Hospital

    Helsinki, Finland · Recruiting

  • Turku University Hospital

    Turku, Finland · Recruiting

  • Institut Bergonie

    Bordeaux, France · Recruiting

  • Marseille University Hospital Timone

    Marseille, France · Recruiting

  • CHU de Poitiers

    Poitiers, France · Recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

  • HM Nou Delfos

    Barcelona, Spain · Recruiting

  • ICO Hospitale

    Barcelona, Spain · Recruiting

  • Vall D'Hebron University Hospital

    Barcelona, Spain · Recruiting

  • HM Sanchinarro

    Madrid, Spain · Recruiting

  • Hospital 12 de Octubre

    Madrid, Spain · Recruiting

  • START Madrid FJD

    Madrid, Spain · Recruiting

  • Ospedale Regionale Bellinzona

    Bellinzona, Switzerland · Recruiting

  • Leicester Royal Infirmary

    Leicester, United Kingdom · Recruiting

  • Royal Marsden Hospital

    London, United Kingdom · Recruiting

  • University Hospital Southampton

    Southampton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.